RxDoctor Payments DataLook up a doctor →

Mario Lacouture, MD

Dermatology · New York, NYNPI 1679563324

Payments from drug & device makers

$2,520,621in general payments, 2019–2025

Across 106 payments — averaging $23,779 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1.3M
  • Novocure Inc.$614K
  • Novartis$515K
  • Janssen Research & Development, LLC$30K
  • Seagen Inc.$20K
  • Roche Products Limited$11K
  • plus $67K from 15 others
$180,747in research payments, 2019–2025

Across 22 payments — averaging $8215.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Onquality Pharmaceuticals (USA) LLC$161K
  • Novartis$13K
  • Deciphera Pharmaceuticals Inc.$4K
  • Novartis Pharma AG$2K
  • F. Hoffmann-la Roche AG$1K

What the payments were for

  • Consulting fees$172,02080%
  • Speaking & faculty fees$15,0007%
  • Grants$18,0008%
  • Travel & lodging$5,2762%
  • Food & beverage$8870%
  • Education$500%
  • Charitable contribution$3,0001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,520,621 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$222,565
Medicare patients
590
Services billed
1,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab172$641,729
OtezlaApremilast13$59,691
Dupixent SyringeDupilumab12$47,409
XolairOmalizumab15$40,482
OpzeluraRuxolitinib Phosphate14$26,715
Clobetasol Propionate182$17,210
Tacrolimus37$7,753
Triamcinolone Acetonide297$5,732
Ammonium Lactate246$5,147
Fluocinolone AcetonideFluocinolone/Shower Cap47$3,347
Fluocinolone Acetonide72$3,196
Silver Sulfadiazine101$2,834
Gentamicin Sulfate47$2,326
Ivermectin15$2,209
Pregabalin68$2,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$6,272$40,48215 claims
Incyte CorporationOpzelura$5,700$26,71514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →